Understanding the System: Adoption of Innovative Diagnostics in Oncology Care
Integrating innovative diagnostics into routine oncology care has the potential to improve how cancer is monitored after treatment. It can help clinicians detect early signs of relapse, tailor follow-up care and avoid unnecessary interventions.
However, whether and how these tests reach people in practice depends on a complex healthcare system. Evidence generation, regulatory processes, HTA decisions, reimbursement pathways and clinical realities all shape what is adopted into routine care.
Lung Cancer Europe is supporting this educational webinar hosted by GUIDE.MRD, alongside Digestive Cancers Europe and PEOF.
The session will share insights from GUIDE.MRD’s work on bringing liquid biopsy testing for the detection of Minimal Residual Disease (MRD) into oncology care.
One focus is circulating tumour DNA (ctDNA) testing. These tests detect tiny fragments of cancer DNA in the bloodstream and may help identify Minimal Residual Disease after treatment. The GUIDE.MRD consortium is validating this approach in lung, pancreatic and colorectal cancer.
Through co-creation with nearly 200 stakeholders, the project developed a system map to understand how ctDNA MRD testing moves through the healthcare system, the roles different actors play, and the barriers and enabling factors that influence adoption.
This webinar will:
Provide a system-wide perspective on the factors influencing adoption of ctDNA MRD testing
Explore how regulatory, HTA and reimbursement processes interact
Invite participants to reflect on whether the identified barriers reflect their own policy or assessment realities
Gather insights to inform the next phase of the project
Participants are encouraged to review the GUIDE.MRD system map ahead of the session and come prepared to share perspectives and questions.
Webinar details
Date: 11 March
Time: 15:00-16.30 CET